Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genfit Hopes To Make Case For First-Line Treatment In NASH

Executive Summary

French company expects Phase III data later in 2019 that will demonstrate elafibranor’s ability to resolve NASH without worsening of fibrosis. Genfit also is partnered with Covance on a potential diagnostic test for NASH.

You may also be interested in...



Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Genfit believes elafibranor’s clean tolerability and safety profile may help narrow the gap between it and Intercept’s OCA, with safety questions delaying OCA’s entry to market. Part two of Scrip’s interview with Genfit’s CEO and COO.

Preparing For The NASH Market: A Conversation With Genfit Execs

As Genfit nears Phase III data for its NASH candidate elafibranor, it has promoted a new CEO and is working ahead on both an NDA filing and facing the commercial challenges of a new therapeutic space.

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Intercept hopes to be first to market in NASH with an indication to treat fibrosis. It also is enrolling a study to show a benefit in NASH patients with cirrhosis.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel